154 related articles for article (PubMed ID: 21498539)
1. Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin.
Song S; Xiong C; Zhou M; Lu W; Huang Q; Ku G; Zhao J; Flores LG; Ni Y; Li C
J Nucl Med; 2011 May; 52(5):792-9. PubMed ID: 21498539
[TBL] [Abstract][Full Text] [Related]
2. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
[TBL] [Abstract][Full Text] [Related]
4. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
5. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5.
Rossin R; Kohno T; Hagooly A; Sharp T; Gliniak B; Arroll T; Chen Q; Hewig A; Kaplan-Lefko P; Friberg G; Radinsky R; Evelhoch JL; Welch MJ; Hwang DR
J Nucl Med; 2011 Jun; 52(6):942-9. PubMed ID: 21571804
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
8. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Tamura K; Kurihara H; Yonemori K; Tsuda H; Suzuki J; Kono Y; Honda N; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Hasegawa K; Kanayama Y; Nozaki S; Kinoshita T; Wada Y; Tazawa S; Takahashi K; Watanabe Y; Fujiwara Y
J Nucl Med; 2013 Nov; 54(11):1869-75. PubMed ID: 24029656
[TBL] [Abstract][Full Text] [Related]
9. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
[TBL] [Abstract][Full Text] [Related]
11. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
12. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
[TBL] [Abstract][Full Text] [Related]
13. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.
Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999
[TBL] [Abstract][Full Text] [Related]
14. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
[TBL] [Abstract][Full Text] [Related]
15. PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.
Luo H; Hong H; Slater MR; Graves SA; Shi S; Yang Y; Nickles RJ; Fan F; Cai W
J Nucl Med; 2015 May; 56(5):758-63. PubMed ID: 25840981
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
19. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
